{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:02:33Z","timestamp":1784628153516,"version":"3.55.0"},"reference-count":24,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Introduction: Extranodal natural killer\/T-cell lymphoma, nasal type (ENKTL-NT), is a rare and aggressive lymphoma for which real-world data from resource-limited settings remain scarce. This study evaluated the efficacy and safety of frontline multimodal treatment strategies for localized ENKTL-NT. Methods: We retrospectively analyzed 62 patients with localized ENKTL-NT treated at the Vietnam National Cancer Hospital between May 2019 and June 2025. Patients received concurrent chemoradiotherapy followed by VIPD or VIDL, or sequential chemoradiotherapy with GELOX\/PGEMOX. Treatment responses, survival outcomes, and toxicities were assessed. Results: The median age was 44 years, and 67.7% of patients had stage I disease. Baseline EBV-DNA positivity was detected in 46.8%, while 54.8% had PINKE scores of 1\u20132. The overall response rate was 93.5%, including an 85.5% complete response rate. Grade 3\u20134 neutropenia was the most common adverse event (18.7%). The estimated 3-year progression-free survival (PFS) and overall survival (OS) rates were 76.3% and 79.5%, respectively. Multivariable Cox analysis identified PINKE risk stratification as an independent predictor of both PFS and OS. Conclusions: Frontline multimodal treatment strategies achieved high response rates, favorable survival outcomes, and manageable toxicities in localized ENKTL-NT. The PINKE score remained an important prognostic factor, supporting risk-adapted treatment selection in routine clinical practice.<\/jats:p>","DOI":"10.3390\/curroncol33070435","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:14:27Z","timestamp":1784621667000},"page":"435","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Frontline Multimodal Treatment Strategies for Localized Extranodal NK\/T-Cell Lymphoma, Nasal Type: A Single-Center Vietnamese Cohort Study"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-9707","authenticated-orcid":false,"given":"Huong","family":"Nguyen Thi Thu","sequence":"first","affiliation":[{"name":"Department of Quan Su Medical Oncology, Vietnam National Cancer Hospital, Hanoi 100000, Vietnam"},{"name":"Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-478X","authenticated-orcid":false,"given":"Dang","family":"Nguyen Van","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam"},{"name":"Department of Head and Neck Radiation Oncology, Vietnam National Cancer Hospital, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen","family":"Le Thi","sequence":"additional","affiliation":[{"name":"Department of Quan Su Medical Oncology, Vietnam National Cancer Hospital, Hanoi 100000, Vietnam"},{"name":"Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5271-9738","authenticated-orcid":false,"given":"Tung","family":"Nguyen Thanh","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam"},{"name":"Department of Hematologic Oncology, Vietnam National Cancer Hospital, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-055X","authenticated-orcid":false,"given":"Manh","family":"Pham Duy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5192-7970","authenticated-orcid":false,"given":"Nga","family":"Tran Thi Giang","sequence":"additional","affiliation":[{"name":"Oncology Center, Thai Binh General Hospital, Thai Binh City 06106, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang","family":"Le Van","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11899-016-0355-9","article-title":"Extranodal NK\/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases","volume":"11","author":"Haverkos","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103237","DOI":"10.1016\/j.critrevonc.2021.103237","article-title":"Extranodal NK\/T cell lymphoma, nasal type: An updated overview","volume":"159","author":"Carlos","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6602502","article-title":"Nasal-type NK\/T cell lymphoma: Clinical features and treatment outcome","volume":"92","author":"Lee","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12185-012-1174-y","article-title":"Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE\/IIE extranodal natural killer\/T cell lymphoma, nasal type: 13-year follow-up in 135 patients","volume":"96","author":"Wang","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CMAR.S328846","article-title":"New Approaches for Treatment of Advanced Extranodal NK\/T-Cell Lymphoma","volume":"14","author":"Yi","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","article-title":"How we treat NK\/T-cell lymphomas","volume":"15","author":"Tse","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yan, Z., Yao, S., Wang, Z., Zhou, W., Yao, Z., and Liu, Y. (2023). Treatment of extranodal NK\/T-cell lymphoma: From past to future. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1088685"},{"key":"ref_9","first-page":"262","article-title":"Clinical and Paraclinical Features, Outcome, and Prognosis of Extranodal Natural Killer\/T-Cell Lymphoma, Nasal Type: A Retrospective Study of 31 Vietnamese Patients","volume":"18","author":"Do","year":"2024","journal-title":"Int. J. Hematol.-Oncol. Stem Cell Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-018-0687-0","article-title":"Treatment of localized extranodal NK\/T cell lymphoma, nasal type: A systematic review","volume":"11","author":"Kim","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/HS9.0000000000000523","article-title":"Extranodal Natural Killer\/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment","volume":"5","author":"Niezink","year":"2021","journal-title":"HemaSphere"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/aol-20-35","article-title":"Overview of the current treatment strategy in extranodal NK\/T-cell lymphoma: From diagnosis to recurrence","volume":"5","author":"Yoon","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, L., Wei, L., Li, X., Cong, J., Ye, J., Yao, N., Yang, J., Wang, L., and Wang, J. (2024). Analysis of the treatment and prognosis of 266 cases of extranodal natural killer\/T-cell lymphoma, nasal type in a single medical center. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1388564"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/bloodadvances.2025019130","article-title":"Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL","volume":"10","author":"Yoon","year":"2026","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/10245332.2016.1264163","article-title":"Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer\/T-cell lymphoma","volume":"22","author":"Wei","year":"2017","journal-title":"Hematology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2021.02.011","article-title":"Modern Radiation Therapy for Extranodal Nasal-Type NK\/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group","volume":"110","author":"Qi","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","article-title":"Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract","volume":"70","author":"Huang","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and Outcomes of Patients With Extranodal Natural Killer\/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.6541","article-title":"Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: An updated analysis of the Japan clinical oncology group study JCOG0211","volume":"30","author":"Yamaguchi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, J., Xue, X., Ma, Y., Wang, X., and Xu, C. (2025). Efficacy and safety of PD-1\/PD-L1 inhibitors for natural killer\/T-cell lymphoma: A single-arm meta-analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13812-x"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70184","DOI":"10.1002\/hem3.70184","article-title":"Autologous stem cell transplantation in NK\/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party","volume":"9","author":"Berning","year":"2025","journal-title":"HemaSphere"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/435\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:17:15Z","timestamp":1784625435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070435"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070435","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}